Association Between Bone Marrow Dosimetric Parameters and Acute Hematologic Toxicity in Anal Cancer Patients Treated With Concurrent Chemotherapy and Intensity-Modulated Radiotherapy
Loren K. Mell(University of California San Diego), Steven J. Chmura(University of Chicago), John C. Roeske(Loyola University Chicago), David A. Schomas(University of California San Diego), Joseph K. Salama(University of California San Diego), Hedy L. Kindler(University of Chicago), Robert C. Miller(Mayo Clinic), Bulent Aydogan(University of Illinois Chicago), Arno J. Mundt(University of California San Diego), Ashesh B. Jani(University of California San Diego), Kiran Devisetty(Wayne State University)
International Journal of Radiation Oncology*Biology*Physics
December 1, 2007
Cited by 231
Related Papers
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
|Journal of Clinical Oncology|2010|840
Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
|Journal of Clinical Oncology|2020|827
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632